24
Participants
Start Date
May 31, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
infigratinib 0.128 mg/kg/day
Oral infigratinib 0.128 mg/kg/day
infigratinib 0.25 mg/kg/day
Oral infigratinib 0.25 mg/kg/day
Murdoch Children's Research Institute, Parkville
Haukeland University Hospital, Bergen
Astrid Lindgren Children's Hospital, Solna
Children's National Hospital, Washington D.C.
Johns Hopkins School of Medicine, Baltimore
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants, Toulouse
Vanderbilt University Medical Center, Nashville
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison
University of Missouri, Columbia
Hôpital Femme Mère Enfant, Bron
Hôpital Universitaire Necker-Enfants Malades, Paris
Childrens Hospital Colorado, Aurora
UCSF Benioff Children's Hospital, Oakland
KK Women's and Children's Hospital, Singapore
London Health Services Center - Children's Hospital of Western Ontario, London
Children's Hospital of Eastern Ontario Research Institute, Ottawa
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine, Montreal
Paediatric Clinical Research Unit at Osla University Hospital, Oslo
Hospital Pediátrico de Coimbra, Coimbra
Hospital Vithas San Jose, Vitoria-Gasteiz
Manchester University, Manchester
Sheffield Children's Hospital, Sheffield
QED Therapeutics, Inc., a Bridgebio company
INDUSTRY